Ultima-Selank 10mg

MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE Selank ,

Products are being shipped without brand labels for security reasons.

The recent surge in biotechnology has paved the way for the examination of new biologically active substances, such as "cognitive enhancers" or "nootropics."

One such substance is Selank, formerly referred to as “TP-7.” It falls under the category of synthetic peptides, which are small proteins designed artificially.

Selank is promoted as an “anti-anxiety” agent and is also said to enhance learning and boost energy levels, allegedly without side effects or addiction risks.

This molecule is relatively small, significantly smaller than most natural proteins. It was developed at the Institute of Molecular Genetics (part of the Russian Academy of Sciences) in collaboration with the V.V. Zakusov Research Institute of Pharmacology (Russian Academy of Medical Sciences), along with its related drug, Semax.

Selank was formulated by merging the sequence of a naturally occurring peptide called tuftsin with another sequence that enhances its molecular stability. Tuftsin is a component of the natural antibody IgG.

Both tuftsin and Selank have shown the potential to lower anxiety and raise serotonin levels in rats, with Selank exhibiting slightly greater effectiveness.

In Russia, Selank has been approved for treating generalized anxiety disorder (GAD) and is also recognized for its nootropic properties. However, it has not received approval from the FDA for any medical conditions. Nevertheless, Selank remains accessible in various countries, often marketed as a “nutritional supplement.”

The specific mechanisms through which Selank operates are not fully understood. It is believed to partially stabilize enkephalins in the bloodstream. Enkephalins are natural peptides that help mitigate the stress response.

However, a study on mice did not find evidence of enkephalin stabilization following Selank administration, and those treated mice did not display significant anti-anxiety effects.

Research suggests that Selank may interact with GABA receptors, as many compounds that bind to these receptors tend to induce sedative effects. In one study, mice treated with Selank showed increased activity in GABA-reliant inhibitory neurons, which correlates with reduced overall brain activity, aligning with a sedative influence.

Moreover, some studies have indicated an increase in BDNF, a crucial neurotrophic factor linked to learning and memory. Some researchers propose that this mechanism may account for some of Selank's asserted cognitive benefits.

Evidence also suggests that Selank may affect the levels of neurotransmitters such as norepinephrine, dopamine, and serotonin in mice. These neurotransmitters are commonly associated with motivation, focus, and pleasure.

However, findings from one study indicated that Selank may elevate norepinephrine levels while decreasing dopamine and serotonin levels. Conversely, another study reported an increase in both norepinephrine and dopamine levels without impacting serotonin. Consequently, the exact effects and mechanisms of Selank remain ambiguous.

In a preliminary clinical study involving 62 participants, those who received Selank noted a reduction in anxiety symptoms, particularly among individuals with existing anxiety disorders.

A separate trial with 60 patients experiencing anxiety and phobias reported similar benefits, with effects lasting for up to a week post-treatment.

Furthermore, in a study with 70 anxiety patients, Selank was found to enhance the effects of phenazepam (a restricted anti-anxiety medication in the U.S.) while reportedly reducing negative side effects, such as drowsiness and memory loss.

Another animal study indicated that Selank could decrease anxiety in mice, with the most anxious subjects showing the most significant behavioral improvements after treatment. Additionally, in a study involving rats who underwent a month of daily treatment, Selank exhibited anti-anxiety effects.

While evidence is limited, these findings suggest that Selank may offer anxiety relief, although further research is essential to establish its effectiveness and safety in humans. If you are experiencing anxiety, it's advisable to consult your healthcare provider about the possibility of using Selank, but never substitute it for prescribed treatments without professional guidance.

One study found Selank to stabilize memory traces (potentially enhancing memory retention) in rats over a 30-day period. However, the method of measuring these effects is unclear since memory traces do not have identifiable locations in the brain.

Another study noted that Selank might also help preserve memory in monkeys. However, there is a lack of adequate human studies to determine the effects of Selank on healthy individuals, and its safety for such users over the short or long term remains uncertain, warranting caution until more research is conducted.

In a particular study, Selank was administered to rats with toxin-induced brain damage, resulting in a restoration of their brain activity to normal levels.

Selank has been observed to reduce symptoms of depression (as indicated by immobility in a forced swimming test) in mice, notably proving more effective at lower doses than at higher ones.

A preliminary animal study indicated that Selank injections increased antioxidant levels in the livers of stressed mice.

In a study involving sedated cats, Selank was shown to lower blood pressure by around 30% for up to 3 minutes and increased cerebral blood flow by approximately 24% for up to 10 minutes. However, these preliminary observations suggest that while Selank may exert some short-term cardiovascular effects on blood flow, the brief duration of these effects raises questions about their clinical significance, particularly as these findings are limited to animals and their applicability to healthy humans is uncertain.

Anxiety is a common symptom associated with alcohol withdrawal. In a study simulating high alcohol intake, rats were given a 10% ethanol solution for 24 weeks and were observed to have reduced anxiety post a 48-hour withdrawal period after receiving Selank.

An animal study indicated that rats on a high-fat diet experienced 35% less weight gain while treated with Selank. Additionally, their total cholesterol levels reportedly dropped over 58%, and blood glucose levels decreased by 23.5%.

In an animal model, mice with breast cancer treated daily with Selank exhibited slower tumor growth and longer survival rates than those not treated. However, these initial findings do not imply that Selank is viable for cancer therapy; substantial further investigation is required to establish any medicinal use for cancer treatment, and under no circumstances should Selank replace conventional cancer treatment modalities.

After Selank treatment, increases in several inflammatory response genes were noted in the spleens of mice, suggesting potential protective benefits against inflammation's detrimental effects.

Selank has been documented to reduce the area of stomach ulcers in animal studies. Some researchers hypothesize this might be due to increased lymph flow, an essential component of the immune system, to the stomach. However, more comprehensive human research is needed to validate this effect and its underlying mechanisms.

Selank was noted to elevate IL-6 levels in the blood cells of patients with depression. IL-6 is an inflammatory protein thought to assist in combatting infections. Furthermore, one cell-based study indicated that Selank may stimulate the release of interferons, which have anti-viral properties.

Though there are suggestions that Selank could offer protection against some viral infections, a mouse study infected with a virus found no anti-viral benefits from Selank treatment, raising doubts about this potential application.